DAY 4 - Wednesday, May 8
RETINA
IVAN, GEFAL: Anti-VEGFs 'equivalent'
Ranibizumab and bevacizumab appear to be equally effective for the treatment of age-related macular degeneration. The results of two large randomized multicenter trials—the IVAN and GEFAL—found that both drugs had similar effects on vision acuity and lesion morphology. » MORE
BLOG FROM ARVO
Editor's blog: Significance
of no statistical difference
As of Tuesday afternoon at this year's Association for Research in Vision and Ophthalmology meeting, all of the head-to-head comparison studies involving the efficacy and the safety of ranibizumab (Lucentis) and bevacizumab (Avastin) are officially IN. » MORE
GLAUCOMA
Glaucoma care costs rising moderately
The cost of caring for patients with glaucoma has risen in the past decade, but at a lower rate than that of general or medical inflation. For Medicare beneficiaries, the greatest expense was not the treatment for glaucoma per se, but rather for cataracts and retinal eye care, said Harry Quigley, MD. » MORE
PEX associated with CVD, CVA
Pseudoexfoliation syndrome (PEX) appears to be significantly associated with both cardiovascular (CVD) and cerebrovascular disease (CVA), according to a new meta-analysis, said Helen Chung, MD. » MORE
DRY EYE
Novel compounds help relieve dry eye
A novel investigational agent appears to help control uncomfortable symptoms of dry eye. The results of OPUS-I, a phase III randomized clinical trial, found that lifitegrast demonstrated superiority to placebo in reducing corneal fluorescein and conjunctival lissamine staining. » MORE
DISCLAIMER:
This information has been independently developed and provided by the editors of Ophthalmology Times. The sponsor does not endorse and is not responsible for the accuracy of the content or for practices or standards of non-sponsor sources.
|
